pythagoras

pythagoras

The previous pop back to old purple bottoms line predicted here in September fizzled a bit at the top peaking early around $2.55 instead of the expected $2.75-3.00. Now we're filling in leg E of the giant corrective wedge since July 2020 $10 high. While the shareholder vote this morning did not meet its quorum requirement, the good news is this morning's retest...

pythagoras

CYDY performance has been dismal since the out-of-protocol "hold your horses!" FDA letter in late May, continuing down in a withering C wave. A great article posted by our friends KenChowder and ohm on Democrat blog dailykos.com yesterday was angrily removed by complainers conditioned to treat any good news on therapeutics as crazy Trumpist propaganda from the...

pythagoras

The FDA explanatory letter this week dropped Cytodyn to $1.77 Wednesday, lower than March $2 low but higher than November $1.63 low. We have a nice clean 5-wave impulse up off the lows back to $2.19 to end the week. It's tiny so far but at least a sign that Wednesday was washout low. So I'm sticking with the year-long 5-wave triangle correction as main thesis...

pythagoras

CYDY has rallied strongly from the $2 floor the past week, doubling to $4.2 this morning on recent understanding that results of CD12 study were hampered by the FDA's 2-dose limitation. With 4-doses spread over the 4-week patient evaluations, more severe patients would likely have been saved. If we conservatively stick to the consolidation triangle idea coming...

pythagoras

Though CYDY managed to rally over the winter from 1.85 to 7.4 on COVID trial results speculation, the 1,2,i,ii,iii nesting sequence we spotted in December never materialized into the expected sequence of higher highs iv,v,4,5 into $8 and $9. The rally stretched and distorted in time ending as a 5-wave B-wave fakeout to $7.4 in February. A sharp C-wave correction...

pythagoras

CYDY is following last week's projection well, spiking parabolically higher to $7 instead of $6 but coming back to $4.5 support area as indicated. Here are my longer-term CYDY wave labels. Interestingly we're once again approaching the original central pitchfork channel started in November 2019 at $.26. That may provide some immediate resistance around $8 but...

pythagoras

Cytodyn appears to be the "last man standing" amongst pharmaceutical treatments intended to stop the Cytokine storm that consumes severe COVID patients. It's Leronlimab trial is still anticipated to significantly reduce mortality and quickly get severe patients off ventilators when all competing drugs have fallen short of proving more than a few days reduced...

pythagoras

So far we haven't seen any indication that FDA or other agencies are in a hurry to approve Cytodyn's Emergency Use Authorization request or otherwise accelerate their trial and manufacturing process, despite Cytodyn's strong Phase II blind trial results and leadership in the race amongst pharmas to convincingly prove out a strongly safe and effective COVID...

pythagoras

CYDY finally published good statistical significance numbers for their mild/moderate COVID study but price has not reacted yet. The fractal micro count (italics) needed one more lower low to 4.2 to complete v of (5) of ii before wave iii of 3 can start. Or we could be in for more abcde of ii consolidation in 4-6.5 range. Either way should rally here.

pythagoras

CYDY has completed 5 micro waves down from i 6.8 area to ii 4.4 area. This should be launching point towards teens from next week's topline efficacy report for Phase II mild/moderate COVID trial. Nader has already hinted that statistically significant positive results will be presented for several meaningful secondary endpoints, if not the loosely defined...

pythagoras

After it's 10-day run to $10, CYDY did not hold expected support at $4.6. That turned out to be just A wave in ABC correction to $2.8 on unexpected FDA-imposed delay in HIV Combo BLA application. That was our most glaring miss in this series of CYDY projections. At least we see strong A=C proportionality suggesting the correction completed Monday the 13th:...

pythagoras

The CYDY consolidation we expected after the spike to $10 may have finished this morning with c wave to $4.75, despite break of $5. Or if trial news is further delayed the triangle could continue to elongate with additional legs (blue path) keeping a short-term bullish bias as long as last week's $4.6 (and $4.75) lows hold.

pythagoras Updated 

But this is a huge fractal growth structure now so it's attack on the teens is not at all done! We should see a triangle consolidation between $6-$9 followed by a trip to $12 minimum, with aftershocks taking it to $15-20 later this year. We kept taking profits on our trading portion up to $9.90 this morning then got a chance to buy back some we'd sold too early at $5-6.

pythagoras

Earlier in the week we said CYDY needed to turn parabolically upwards in a steeper channel for technicals to catch up with the rosy speculative fundamentals of high likelihood COVID approval in July. We got the slope of this new channel perfect but it started even quicker than projected. Here's an updated fractal projection that fills the gap at 6, goes straight...

pythagoras

This week CYDY has reached the mid-$4 range predicted in April to complete the fractal growth channel since late 2019 lows at $.26. Since April, we know Cytodyn has treated at least 80 COVID patients in its Phase II mild-moderate trial, 70 in its Phase III severe trial and at least 75 EIND emergency patients outside blind trials. We know from Dr. Bruce...

pythagoras

Here's another possible fractal path for CYDY over coming weeks. It appears to be consolidating and basing in 2.76-3.2 zone ready for an attack on 3.57-3.65, then 3.83-4 and eventually the old 2011 all-time high around 4.4 (when there were WAY fewer outstanding shares!). This sort of stair-stepped march-up can be expected so long as trial results and partnering...

pythagoras Updated 

The super-hot bio-tech startup Cytodyn with their humanized monoclonal antibody Leronlamib has been on a tear up 1000% since November 2019 lows ($.26). The rally has been driven by many press releases: stabilized financing and marketing contracts, amazing results in their early cancer trials and now serendipitous immunological application to severe coronavirus...

pythagoras

Here's a closeup on the CYDY micro-fractal action this week. Notice the clear 5 wave structure in each triangle up-leg. Trimming at the top and buying back at the bottom of the triangle for a few days before wave V comes on what -- BLA submission news?